1139717-39-7

Upstream product

• 41288-96-4 6-chloropyridine-3-ol 
• 168267-41-2 (3,4-difluorophenyl)boronic acid 

Downstream Products

• 1139717-40-0 [5-(3,4-difluorophenoxy)-pyridin-2-yl]-(3,4-difluorophenyl)amine 
• 1139717-41-1 [5-(3,4-difluorophenoxy)-pyridin-2-yl]-(4-fluoro-3-methoxyphenyl)amine 
• 1139717-46-6 [5-(3,4-difluorophenoxy)-pyridin-2-yl]-(3-morpholin-4-ylphenyl)amine 
• 1139717-42-2 [5-(3,4-difluorophenoxy)-pyridin-2-yl]-(3-fluoro-4-morpholin-4-yl-phenyl)amine 
• 1139717-44-4 [5-(3,4-Difluorophenoxy)-pyridin-2-yl]-[3-(2-methoxyethoxy)-phenyl]amine 
• 1139717-47-7 [5-(3,4-difluorophenoxy)-pyridin-2-yl]-[3-(4-methylpiperazin-1-yl)phenyl]amine 
• 1139717-45-5 5-(3,4-difluorophenoxy)-pyridin-2-yl-[3-(2-morpholin-4-ylethoxy)-phenyl]amine 

Relevant academic research and scientific papers

MRGPRX2 ANTAGONISTS AND USES THEREOF

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.

PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES

a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m=0-1, n=0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen halogen, CF3, CN, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R3 is hydrogen, halogen, CF3, CN, OR8, SR8 or SO2R11; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R7 is hydrogen, C1-6 alkyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR9; R8 is hydrogen or C1-6 alkyl optionally substituted by fluorine, C1-6 alkoxy or NR9R10, R9 is hydrogen, C1-6 alkyl or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8, NR9R10 Or OCF3; R10 is hydrogen, C1-6 alkyl, C1-6 alkenyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8 or OCF3; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR9, S and O; and R11 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR8 is provided. The compounds are useful in treating amyloid related diseases.